Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Tolerability of bosutinib vs asciminib in heavily pre-treated patients with CML

Michael Deininger • 21 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia Asciminib Bosutinib

Michael Deininger, MD, PhD, The Medical College of Wisconsin, Milwaukee, WI, compares the safety of bosutinib and asciminib in heavily pre-treated patients with chronic myeloid leukemia (CML). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Novartis, BMS, Incyte, Takeda, Blueprint, Cogent, CTI.

More from Michael Deininger

1:24
Ongoing studies in CML: investigating asciminib toxicity and improving TFR rates
Michael Deininger • 21 Oct 2022
1:33
ESH CML workshop highlights: 3D genomics and nuclear organization
Michael Deininger • 21 Oct 2022
1:10
Final results of the BFORE trial: bosutinib vs imatinib in CP-CML
Michael Deininger • 21 Oct 2022
1:37
OPTIC: Ponatinib in chronic-phase CML
Michael Deininger • 12 Dec 2021

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals